CPRX Catalyst Pharmaceuticals Inc.

3.84
+0.05  (+1%)
Previous Close 3.79
Open 3.82
Price To Book 7.68
Market Cap 394960347
Shares 102,854,257
Volume 1,581,526
Short Ratio
Av. Daily Volume 3,284,952

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Firdapse
Spinal Muscular Atrophy (SMA) Type 3
Phase 3 data due 2H 2019.
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 2H 2019.
Firdapse
Congenital Myasthenic Syndromes (CMS)
FDA approval announced November 28, 2018.
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)